Inhibitor Therapeutics (INTI) awards CEO 50,000 restricted common shares

Rhea-AI Filing Summary

ODONNELL FRANCIS E JR reported acquisition or exercise transactions in this Form 4 filing.

Inhibitor Therapeutics, Inc. reported that Chief Executive Officer Francis E. O'Donnell Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026, at $0.00 per share as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. Following this award, he directly holds a total of 150,000 common shares.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 1 txn

Insider ODONNELL FRANCIS E JR

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 150,000 shares (Direct)

Footnotes (1)

1. F1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

Key Figures

Restricted shares granted: 50,000 shares Grant price per share: $0.00 Direct holdings after grant: 150,000 shares +1 more

4 metrics

Restricted shares granted 50,000 shares Grant to CEO Francis E. O'Donnell Jr. on 2026-05-04

Grant price per share $0.00 Reported price for compensatory restricted stock award

Direct holdings after grant 150,000 shares Common stock directly owned by CEO following the transaction

Transaction date 2026-05-04 Date the restricted common stock was granted

Key Terms

restricted common stock, 2025 Equity Incentive Plan, shareholder approval

3 terms

restricted common stock financial

"Represents restricted common stock issued to the Reporting Person as compensation"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

2025 Equity Incentive Plan financial

"as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject"

shareholder approval financial

"2025 Equity Incentive Plan, subject to shareholder approval"

Shareholder approval is a formal vote by a company’s owners—its shareholders—to accept or reject major corporate actions such as mergers, sale of significant assets, board member elections, or changes to the company’s governing rules. It matters to investors because it gives them direct influence over decisions that affect the company’s value and risk profile; think of it like neighbors voting on a large renovation that will change property values, where approval lets the project proceed and rejection stops it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 11:56 AM Accepted by SEC EDGAR 08/04/2026 - 11:55 AM Learn about SEC filing dates

FAQ

What insider transaction did INTI report for its CEO?

Inhibitor Therapeutics (INTI) reported that CEO Francis E. O'Donnell Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026, at $0.00 per share as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval.

How many INTI shares does the CEO hold after this Form 4 transaction?

After the reported grant, CEO Francis E. O'Donnell Jr. directly holds 150,000 shares of Inhibitor Therapeutics common stock. This reflects the addition of 50,000 restricted shares issued as compensation under the company’s 2025 Equity Incentive Plan.

What type of INTI securities were granted to the CEO?

The CEO received restricted common stock of Inhibitor Therapeutics. The 50,000-share award was issued as compensation pursuant to the company’s 2025 Equity Incentive Plan and is expressly described as restricted common stock in the filing’s footnote.

Was the INTI CEO stock grant made under a trading plan?

The filing indicates the grant was not made under a Rule 10b5-1 trading plan, as the related checkbox is not marked. Instead, the award is described as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval.

What is the consideration and pricing for the INTI CEO share grant?

The 50,000 restricted common shares granted to the CEO carry a reported price of $0.00 per share, reflecting their nature as equity compensation rather than a cash purchase. They were issued under the 2025 Equity Incentive Plan, subject to shareholder approval.

What shareholder approval condition applies to the INTI CEO stock award?

The footnote states that the 50,000 restricted shares were issued as compensation subject to shareholder approval of Inhibitor Therapeutics’ 2025 Equity Incentive Plan. This condition governs the compensatory grant reported in the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ODONNELL FRANCIS E JR

(Last) (First) (Middle)

C/O INHIBITOR THERAPEUTICS, INC.,

3014 WEST PALMIRA AVE SUITE 302

(Street)

TAMPA FLORIDA 33629

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		50,000(1)	A	$0	150,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

	/s/ Francis E O'Donnell	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)